New generation versus conventional antipsychotics [3] (multiple letters)

Lancet

Volumn 362, Issue 9381, 2003, Pages 404-405

  Geddes, John ^a   Harrison, Paul ^a   Freemantle, Nick ^b   Leucht, Stephan ^c   Wahlbeck, Kristian ^e   Engel, Rolf ^d   Hamann, Johannes ^c   Kissling, Werner ^c  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; ZIPRASIDONE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0042671164     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14035-4     Document Type: Letter

References (5)

1. S Leucht K Wahlbeck J Hamann W Kissling New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 361 2003 1581 1589
2. JR Geddes N Freemantle P Harrison PE Bebbington Atypical antipsychotics in the treatment of schizophrenia—systematic overview and meta-regression analysis BMJ 321 2000 1371 1376
3. TC Smith DJ Spiegelhalter A Thomas Bayesian approaches to random-effects meta-analysis: a comparative study Stat Med 14 1995 2685 2699
4. JR Geddes Prevention of relapse in schizophrenia N Engl J Med 346 2002 56 58
5. JG Csernansky R Mahmoud R Brenner Riseridone Ris-USA-79 Study Group A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia N Engl J Med 346 2002 16 22